VSV vector-based highly pathogenic h5 subtype avian influenza inactivated vaccine and method for preparing same

By constructing a recombinant VSV vector lacking surface envelope proteins and inserting the NA and HA genes of the H5 subtype avian influenza virus strain, an inactivated vaccine was prepared. This solved the problems of immunogenicity and safety of VSV vector vaccines, and achieved efficient expression of HA and NA proteins, resulting in high safety, strong immunogenicity, and DIVA compatibility.

WO2026130227A1 Publication Date: 2026-06-25ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD +1
0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/141937
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-20
Filing Date
2025-12-12
Publication Date
2026-06-25

AI Technical Summary

Technical Problem

In the existing technology, highly pathogenic H5 subtype avian influenza vaccines using VSV vectors pose risks to immune safety, and the immunogenicity and antigen abundance of inactivated viruses are poor, making it difficult to effectively express HA and NA proteins.

Method used

Using vesicular stomatitis virus lacking the surface envelope protein gene as a vector, the NA and HA genes of the H5 subtype avian influenza virus strain were inserted. Recombinant viruses were constructed using reverse genetics technology, and after inactivation treatment, they were combined with pharmaceutically or veterinarily acceptable vectors, excipients, mediators or adjuvants to prepare inactivated vaccines.

Benefits of technology

The inactivated vaccine against highly pathogenic H5 subtype avian influenza has achieved high safety and strong immunogenicity, can effectively express HA and NA proteins, is compatible with the DIVA strategy, and can distinguish between infected and immunized animals.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the field of biological vaccine research and development technology, and in particular, to a VSV vector-based highly pathogenic H5 subtype avian influenza inactivated vaccine and a method for preparing same. The method comprises: using a vesicular stomatitis virus with the deletion of the surface envelope protein gene as a vector, inserting the NA gene and the HA gene of an H5 subtype highly pathogenic avian influenza virus strain between the M gene and the L gene of the vector in the form of an expression cassette, and acquiring a recombinant virus by means of rescue via reverse genetic technology; inoculating the recombinant virus into susceptible cells, culturing for replication and proliferation, and then harvesting a viral solution; inactivating the viral solution to acquire an inactivated viral solution; and adding the inactivated viral solution to a pharmaceutically or veterinarily acceptable carrier, excipient, medium, or adjuvant to acquire an inactivated vaccine. The provided H5 subtype avian influenza inactivated vaccine can induce a high hemagglutination inhibition titer of avian influenza virus on day 21 after chick immunization. The provided inactivated vaccine has good safety and immunogenicity.
Need to check novelty before this filing date? Find Prior Art